FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) announced that Chairman & CEO Pete O’Heeron will present on the main stage at the A4LI H-SPAN Summit, June 29–July 1, 2026, at Georgetown University.

The three-day summit combines longevity research, innovation policy, and a Congressional Briefing to advance healthier human lifespans and policy advocacy.

News Market Reaction – FBLG

+6.24%

9 alerts

+6.24% News Effect

+13.6% Peak Tracked

-3.4% Trough Tracked

+$1M Valuation Impact

$19M Market Cap

0.6x Rel. Volume

On the day this news was published, FBLG gained 6.24%, reflecting a notable positive market reaction. Argus tracked a peak move of +13.6% during that session. Argus tracked a trough of -3.4% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $19M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Patent portfolio size: 270+ patents issued and pending Summit dates: June 29–July 1, 2026 Event duration: Three-day summit

3 metrics

Patent portfolio size 270+ patents issued and pending FibroBiologics IP estate described in summit announcement

Summit dates June 29–July 1, 2026 A4LI H-SPAN Summit schedule at Georgetown University

Event duration Three-day summit Length of H-SPAN longevity policy and science event

Market Reality Check

Price: $0.2480 Vol: Volume 477,455 is at 0.4x...

low vol

$0.2480 Last Close

Volume Volume 477,455 is at 0.4x the 20-day average of 1,201,021, indicating subdued trading interest pre-announcement. low

Technical Shares at 0.2515 are trading below the 200-day MA of 0.55 and 87.42% under the 52-week high of 2.

Peers on Argus

While FBLG is near its 52-week low, 3 biotech peers (ICU, GDTC, AKTX) in the mom...

3 Down

While FBLG is near its 52-week low, 3 biotech peers (ICU, GDTC, AKTX) in the momentum scan are all moving down (median move about -6.3%), suggesting broader sector pressure rather than a company‑specific move tied to this conference news.

Historical Context

5 past events · Latest: Feb 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 05	Patent issuance	Positive	-9.2%	Canadian patent covering fibroblast-based cachexia treatment and inflammation reduction.
Jan 20	Conference presentation	Positive	-3.7%	CEO presentation at DealFlow Discovery Conference and investor meetings scheduling.
Jan 07	Shareholder update	Positive	+32.3%	Shareholder letter detailing 2025 clinical, IP, manufacturing and financing milestones.
Jan 06	Conference presentation	Positive	+6.8%	Announcement of CEO presentation at BFC Global Healthcare investment conference.
Jan 05	Preclinical results	Positive	+1.5%	Positive preclinical FSdC spheroid data in degenerative disc disease models.

Pattern Detected

Positive or promotional news has often seen mixed follow-through, with both sharp gains and notable selloffs in prior events.

Recent Company History

Over the past months, FibroBiologics has combined scientific and corporate milestones with frequent investor outreach. Patent grants, such as the Canadian cachexia patent on Feb 5, 2026, and positive preclinical FSdC data on Jan 5, 2026, highlight its fibroblast-based pipeline. Multiple conference presentations and a shareholder letter on Jan 7, 2026 outlined clinical, IP, and financing progress. Today’s summit-speaking announcement fits the pattern of visibility and positioning rather than a discrete clinical or financial catalyst.

Market Pulse Summary

The stock moved +6.2% in the session following this news. A strong positive reaction aligns with pri...

Analysis

The stock moved +6.2% in the session following this news. A strong positive reaction aligns with prior instances where visibility or scientific updates, such as the Jan 7, 2026 shareholder letter, preceded notable gains. However, the stock remained far below its 2 52-week high and faces ongoing Nasdaq listing and dilution risks from past financings. Any outsized move could be vulnerable if sector weakness resumes or enthusiasm for non-clinical milestones fades.

Key Terms

fibroblasts, thymic regenerative biology, cellular therapeutics

3 terms

fibroblasts medical

"…therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials…"

Fibroblasts are common cells in connective tissue that manufacture the structural proteins and fibers—like collagen—that form and repair the body's scaffolding, helping wounds heal and tissues hold their shape. For investors, fibroblasts matter because they are frequent targets or tools in drug development, regenerative medicine and safety testing: changes in their behavior can signal whether a therapy will work, cause side effects or enable new medical products, much like a construction crew determines the strength and finish of a building.

thymic regenerative biology medical

"“Thymic regenerative biology is a potentially transformative area of research…"

A field of biomedical research and development focused on restoring or regrowing the thymus, the small organ that produces T-cells—the immune system’s frontline defenders. For investors, advances here could create new therapies that strengthen immune responses in aging adults, people with immune deficiencies, or transplant recipients, potentially opening large markets but also carrying long development timelines, regulatory hurdles, and clinical risk. Think of it as repairing a factory that builds your body’s security guards.

cellular therapeutics medical

"…including breakthroughs in cellular therapeutics and strategies for translating research…"

Cellular therapeutics are medical treatments that use living cells as the active ingredient to repair, replace, or modulate biological function—for example using immune cells to fight disease or stem cells to regenerate tissue. They matter to investors because they can offer powerful, often one-time or durable benefits that command high prices, but they also carry unique risks and costs from complex manufacturing, strict regulation, and uncertain clinical outcomes—think of them as a living product rather than a simple pill.

AI-generated analysis. Not financial advice.

HOUSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chairman and CEO Pete O’Heeron has been invited to serve as a main stage speaker at the upcoming A4LI’s H-SPAN Summit at Georgetown University.

The summit, taking place June 29–July 1, 2026, is hosted by the Alliance for Longevity Initiatives (A4LI) and is recognized as a premier event bringing together leaders, innovators, policymakers, and advocates from across the globe to advance legislative and scientific initiatives aimed at promoting healthier human lifespans. The three-day event will be held on the Georgetown University Capitol Campus and will culminate in a Congressional Briefing and Hill Day on Capitol Hill.

“We are proud to have Pete represent FibroBiologics on the H-SPAN stage,” said Dylan Livingston, Founder/CEO of Alliance For Longevity Initiatives. “Thymic regenerative biology is a potentially transformative area of research for extending healthy human lifespan, and Pete is a trailblazer in this space. FibroBiologics’ commitment to addressing chronic diseases aligns directly with the goals of the summit and A4LI’s mission of accelerating innovation that extends human healthspan.”

At the summit, Mr. O’Heeron will address an expert audience of researchers, biotech executives, and policy leaders on the next frontier of longevity science, including breakthroughs in cellular therapeutics and strategies for translating research into real-world clinical impact.

The Summit unites scientific advancement with policy frameworks, with Day 1 focusing on cutting-edge longevity research, Day 2 on frameworks for innovation policy, and Day 3 on direct advocacy with members of Congress to elevate national healthspan priorities. This year’s agenda reflects growing momentum in the biotech longevity ecosystem and underscores the importance of cross-sector collaboration.

“I’m honored to be selected as one of the main stage speakers for the H-SPAN Summit and to contribute to this important national dialogue,” said Pete O’Heeron. “FibroBiologics is committed to advancing therapies that prevent and treat chronic disease along with extending human life, and summits like this are essential for aligning scientific innovation with policy action.”

The Alliance for Longevity Initiatives (A4LI) is a 501(c)(4) organization advancing legislation and policies that aim to increase healthy human lifespan and accelerate equitable access to next-generation therapies. The H-SPAN Summit has quickly become a leading forum for shaping America’s longevity policy agenda.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips 
Russo Partners 
(347) 956-7697 
Elizabeth.phillips@russopartnersllc.com

For more information on A4LI’s H-SPAN Summit at Georgetown University or to register, visit: https://a4li.org/h-span-summit-dc/

FAQ

When will FibroBiologics (FBLG) present at the A4LI H-SPAN Summit?

FibroBiologics CEO Pete O’Heeron will speak on the main stage June 29–July 1, 2026. According to FibroBiologics, the summit spans three days at Georgetown University and concludes with a Congressional Briefing and Hill Day to connect science with policy advocacy.

What topics will Pete O’Heeron cover at the H-SPAN Summit for FBLG (FBLG)?

He will discuss advances in longevity science and cellular therapeutics and translating research into clinical impact. According to FibroBiologics, the talk targets researchers, biotech executives, and policy leaders and links thymic regenerative biology to healthspan policy.

Where is the A4LI H-SPAN Summit taking place for FibroBiologics’ presentation?

The summit is held on the Georgetown University Capitol Campus with a Capitol Hill briefing. According to FibroBiologics, the event runs June 29–July 1, 2026, and culminates in direct advocacy through a Congressional Briefing and Hill Day.

Why is FibroBiologics (FBLG) participating in the A4LI H-SPAN Summit?

FibroBiologics says participation aligns with its focus on therapies to prevent and treat chronic disease and extend human healthspan. According to FibroBiologics, the summit fosters cross-sector collaboration between science and policy to advance longevity initiatives.

Who is hosting the H-SPAN Summit where FBLG’s CEO will speak?

The Alliance for Longevity Initiatives (A4LI) is hosting the summit at Georgetown University June 29–July 1, 2026. According to FibroBiologics, A4LI organizes the event to bring leaders and policymakers together to shape national longevity policy.

How does the H-SPAN Summit program relate to FibroBiologics’ research focus (FBLG)?

The summit pairs cutting-edge longevity research with innovation policy and advocacy to accelerate clinical translation. According to FibroBiologics, this format complements its thymic regenerative biology and cellular therapeutics efforts aimed at extending healthy human lifespan.